119 related articles for article (PubMed ID: 11264596)
61. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
62. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?
Linsley PS
J Exp Med; 1995 Aug; 182(2):289-92. PubMed ID: 7543133
[No Abstract] [Full Text] [Related]
63. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
[TBL] [Abstract][Full Text] [Related]
64. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
[TBL] [Abstract][Full Text] [Related]
65. Induction of T cell anergy in the absence of CTLA-4/B7 interaction.
Frauwirth KA; Alegre ML; Thompson CB
J Immunol; 2000 Mar; 164(6):2987-93. PubMed ID: 10706686
[TBL] [Abstract][Full Text] [Related]
66. The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance.
Lespagnard L; Mettens P; De Smedt T; Bazin H; Urbain J; Leo O; Moser M
Int Immunol; 1998 Mar; 10(3):295-304. PubMed ID: 9576617
[TBL] [Abstract][Full Text] [Related]
67. Crystallization and preliminary X-ray analysis of CTLA-4 (CD152) membrane-external domain.
Chang CY; Fenderson WH; Lavoie TB; Peach RJ; Einspahr HM; Sheriff S
Acta Crystallogr D Biol Crystallogr; 2000 Nov; 56(Pt 11):1468-9. PubMed ID: 11053855
[TBL] [Abstract][Full Text] [Related]
68. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.
Schwartz JC; Zhang X; Fedorov AA; Nathenson SG; Almo SC
Nature; 2001 Mar; 410(6828):604-8. PubMed ID: 11279501
[TBL] [Abstract][Full Text] [Related]
69. Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28.
Follows ER; McPheat JC; Minshull C; Moore NC; Pauptit RA; Rowsell S; Stacey CL; Stanway JJ; Taylor IW; Abbott WM
Biochem J; 2001 Oct; 359(Pt 2):427-34. PubMed ID: 11583591
[TBL] [Abstract][Full Text] [Related]
70. Expression of inducible lymphocyte costimulatory molecules in human renal allograft.
Biancone L; Segoloni G; Turello E; Donati D; Bussolati B; Piccoli G; Camussi G
Nephrol Dial Transplant; 1998 Mar; 13(3):716-22. PubMed ID: 9550652
[TBL] [Abstract][Full Text] [Related]
71. B70 antigen is a second ligand for CTLA-4 and CD28.
Azuma M; Ito D; Yagita H; Okumura K; Phillips JH; Lanier LL; Somoza C
Nature; 1993 Nov; 366(6450):76-9. PubMed ID: 7694153
[TBL] [Abstract][Full Text] [Related]
72. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.
Lumsden JM; Roberts JM; Harris NL; Peach RJ; Ronchese F
J Immunol; 2000 Jan; 164(1):79-85. PubMed ID: 10604996
[TBL] [Abstract][Full Text] [Related]
73. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
Krummel MF; Sullivan TJ; Allison JP
Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
[TBL] [Abstract][Full Text] [Related]
74. Role of B7-CD28/CTLA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES.
Hidi R; Riches V; Al-Ali M; Cruikshank WW; Center DM; Holgate ST; Djukanovic R
J Immunol; 2000 Jan; 164(1):412-8. PubMed ID: 10605037
[TBL] [Abstract][Full Text] [Related]
75. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
[TBL] [Abstract][Full Text] [Related]
76. CD28/CTLA-4 and CD80/CD86 families: signaling and function.
Slavik JM; Hutchcroft JE; Bierer BE
Immunol Res; 1999; 19(1):1-24. PubMed ID: 10374692
[TBL] [Abstract][Full Text] [Related]
77. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
Lenschow DJ; Ho SC; Sattar H; Rhee L; Gray G; Nabavi N; Herold KC; Bluestone JA
J Exp Med; 1995 Mar; 181(3):1145-55. PubMed ID: 7532678
[TBL] [Abstract][Full Text] [Related]
78. Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.
Belani R; Weiner GJ
Immunology; 1996 Feb; 87(2):271-4. PubMed ID: 8698390
[TBL] [Abstract][Full Text] [Related]
79. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.
Romo-Tena J; Gómez-Martín D; Alcocer-Varela J
Autoimmun Rev; 2013 Oct; 12(12):1171-6. PubMed ID: 23851140
[TBL] [Abstract][Full Text] [Related]
80. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
Carreno BM; Collins M
Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
